Podcast 683: Zofran vs. Haldol for Cannabinoid Hyperemesis Syndrome - The Emergency Medical Minute

Podcast 683: Zofran vs. Haldol for Cannabinoid Hyperemesis Syndrome

Contributor:  Jared Scott, MD

Educational Pearls:

  • Around 30 patients with cannabinoid hyperemesis syndrome (CHS) randomized treatment in three arms with 8mg Zofran, Haldol 0.05 mg/kg, and Haldol 0.1 mg/kg
  • Haldol arms performed better on all measures compared to Zofran
  • Extrapyramidal symptoms were significantly higher in the Haldol group than Zofran, especially the high-dose Haldol group

References

Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. Ann Emerg Med. 2021;77(6):613-619. doi:10.1016/j.annemergmed.2020.08.021

Summarized by John Spartz, MS4 | Edited by Erik Verzemnieks, MD

 

The Emergency Medical Minute is excited to announce that we are now offering AMA PRA Category 1 credits™ via online course modules. To access these and for more information, visit our website at www.emergencymedicalminute.com/cme-courses/ and create an account. 

Donate to EMM today!

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

 

Stay up to date by
joining our mailing list!